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DMBA = 7,12-dimethylbenz(a)anthracene; EGC = epigallocatechin; EGF = epidermal growth factor; EGCG = epigallocatechin-3 gallate; ER =
oestrogen receptor; ERE = oestrogen response element; HRT = hormone replacement therapy; IGF = insulin-like growth factor; SRC = steroid
receptor coactivator; TGF = transforming growth factor.
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Introduction
The current mortality rate for premenopausal breast
cancer is approximately fourfold higher in the Western
World than in Far East Asian nations [1]. Migrants from
Asia to the USA typically acquire a breast cancer risk
associated with their host nation by the second generation,
suggesting a direct influence of environmental rather than
genetic factors [2,3]. The reduced prevalence of breast
cancer in Far East Asian nations directly correlates with
the consumption of a staple diet that is abundant in soy
[4]. Asian populations consume an approximate mean
daily soy intake of 10–50 g, declining to just 1–3 g in the
USA. The recent adoption of a more westernized diet
correlates with an increased breast cancer incidence in
urban areas of Japan, Singapore and China [5]. Soy-
containing foods are an abundant source of phyto-
oestrogens, and research suggests that these compounds
may exhibit chemoprotectant activity against a number of
human cancers, including colon carcinoma and hormone-
dependent cancers of the breast and prostate [6]. This
report focuses on the putative chemopreventive role of
phyto-oestrogens in breast cancer, providing a compre-
hensive review of the published literature to date.
Phyto-oestrogen classification and metabolism
Phyto-oestrogens may be classified into a number of
principal groups [2,7–9]: the isoflavones (genistein, daidzein,
biochanin A), the lignans (enterolactone, enterodiol), the
coumestans (coumestrol) and the stilbenes (resveratrol).
As illustrated in Fig. 1, all are polyphenols sharing
structural similarity with the principal mammalian oestrogen
17β-oestradiol. Shared features include the presence of a
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Abstract
Phyto-oestrogens are polyphenol compounds of plant origin that exhibit structural similarity to the
mammalian steroid hormone 17β-oestradiol. In Asian nations the staple consumption of phyto-
oestrogen-rich foodstuffs correlates with a reduced incidence of breast cancer. Human dietary
intervention trials have noted a direct relationship between phyto-oestrogen ingestion and a favourable
hormonal profile associated with decreased breast cancer risk. However, these studies failed to
ascertain the precise effect of dietary phyto-oestrogens on the proliferation of mammary tissue.
Epidemiological and rodent studies crucially suggest that breast cancer chemoprevention by dietary
phyto-oestrogen compounds is dependent on ingestion before puberty, when the mammary gland is
relatively immature. Phyto-oestrogen supplements are commercially marketed for use by
postmenopausal women as natural and safe alternatives to hormone replacement therapy. Of current
concern is the effect of phyto-oestrogen compounds on the growth of pre-existing breast tumours.
Data are contradictory, with cell culture studies reporting both the oestrogenic stimulation of oestrogen
receptor-positive breast cancer cell lines and the antagonism of tamoxifen activity at physiological
phyto-oestrogen concentrations. Conversely, phyto-oestrogen ingestion by rodents is associated with
the development of less aggressive breast tumours with reduced metastatic potential. Despite the
present ambiguity, current data do suggest a potential benefit from use of phyto-oestrogens in breast
cancer chemoprevention and therapy. These aspects are discussed.
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pair of hydroxyl groups and a phenolic ring, which is
required for binding to the oestrogen receptor (ER)
subtypes  α and  β. The position of the hydroxyl groups
appears to be important in determining ER binding ability
and transcriptional activation, with maximal potency
achieved at positions four, six and seven [10–12]. The
isoflavones are naturally found in soybeans and soy-based
food products, including tofu, soy milk, textured soy
protein and miso. Lignans are present in flaxseed and
most fruit and vegetables, and the predominant dietary
source of stilbenes is peanuts, grapes and red wine
[7,13]. The coumestans are much less frequently consumed
within the human diet, but they are more potent activators
of ER signalling pathways than are the isoflavones genistein
and daidzein [10,14]. By contrast, the stilbene resveratrol
is the least potent activator of ER signalling [11].
The isoflavones are present in soy as β-glucosides.
Metabolism by the gastrointestinal microflora yields a
number of metabolites including equol and O-desmethyl-
angolensin. Parental compounds and their metabolites are
absorbed into the bloodstream, becoming rapidly detectable
in the plasma and urine [15–19]. Plasma isoflavone
concentrations are considerably elevated in Asian
populations as compared with in Western ones. A recent
comparison of Japanese and UK females revealed an
almost 20-fold increase in plasma genistein levels in the
Japanese cohort, and daidzein concentrations were similarly
elevated by 18-fold [20]. Plasma isoflavone concen-
trations may accumulate to approximately 100- to 1000-
fold higher than endogenous oestradiol levels following
the ingestion of soy-rich meal. However, research
suggests a decreased ER binding affinity of isoflavone
compounds as compared with the mammalian oestrogens
[9,10,21,22]. Competition binding assays revealed a 50-
fold lower binding affinity of genistein for cytoplasmic ER
sites as compared with 17β-oestradiol [23].
The complete metabolic activation of soy isoflavones is
proposed to occur locally within target tissue. In support
of this hypothesis, the analysis of tissue culture super-
natants from genistein and biochanin A treated MCF-7
and T47-D cells revealed the presence of hydroxylated
and methylated isoflavone metabolites [24]. Current
research suggests a role for the CYP family of cytochrome
P450 enzymes in the intratumour metabolism of phyto-
Figure 1
Structural comparison of the natural and synthetic oestrogens (a) 17β-oestradiol and (b) diethylstilbestrol with the principal classes of
phyto-oestrogen: the stilbene (c) resveratrol, lignan compounds (d) enterolactone and (e) enterodiol, the coumestan (f) coumestrol, and
isoflavones (g) genistein, (h) daidzein and (i) biochanin A.
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oestrogen compounds [25,26]. The CYP1B1 enzyme is
expressed in a wide range of human tumour types,
including breast [27]; however, expression is absent
within normal tissue. CYP1B1 is proposed to catalyze the
hydroxylation of resveratrol to yield the related stilbene
piceatannol [26]. Piceatannol is a tyrosine kinase inhibitor
with antileukaemic properties, which differs in structure
from resveratrol by the presence of an additional hydroxyl
group. A number of plant flavonoids are also putative
substrates for the CYP family of enzymes [25]. Maubach
and coworkers [28] recently reported the use of high-
performance liquid chromatography to quantify isoflavones
in normal breast biopsy tissue following consumption of
soy for 5 consecutive days. Equol concentrations were
approximately fivefold higher in the breast tissue
homogenates than in serum, providing further evidence for
the metabolism of phyto-oestrogen compounds within
mammary tissue.
Role of phyto-oestrogens in breast cancer
Serum concentrations of 17β-oestradiol are approximately
40% lower in Asian women than in their Caucasian
counterparts [29]. A low lifetime exposure to oestrogen is
associated with a reduced risk for breast cancer. Human
dietary intervention studies revealed a direct association
between the modest consumption of soy products and a
reduction in circulating steroid hormone levels. Daily
consumption of 154 mg isoflavones for the duration of a
single menstrual cycle correlated with substantially
decreased plasma concentrations of 17β-oestradiol and
progesterone in a cohort of premenopausal women [18].
A longer term study conducted by Kumar and coworkers
[30] similarly reported a moderate decrease in serum
oestradiol and oestrone levels following daily ingestion of
40 mg isoflavones for 3 months. Menstrual cycle length
was increased by 3.52 days, and the follicular phase of
the cycle was extended by 1.46 days. Increased menstrual
cycle length may serve to reduce the total number of
cycles per lifetime, therefore decreasing the total exposure
of breast epithelia to endogenous oestrogens. Conversely,
a year-long dietary intervention trial involving 34 premeno-
pausal women failed to reveal a significant effect of
100 mg/day isoflavone consumption either on menstrual
cycle length or on serum levels of various steroid hormones,
including oestrone, oestradiol and progesterone [19].
As a possible explanation for these contradictory data, a
study conducted by Duncan and coworkers [31] revealed
differential hormonal effects of soy isoflavones depending
on the ability to excrete the daidzein metabolite equol. Daily
ingestion of 10mg soy protein by premenopausal equol
excretors resulted in a hormonal profile associated with
reduced breast cancer risk, characterized by lowered plasma
levels of oestrone, oestrone–sulphate and testosterone.
Hormone levels, however, remained unchanged in the
equol nonexcretors after soy ingestion.
The reduction in steroid hormone levels by phyto-
oestrogens is proposed to occur via the direct regulation
of 17β-oestradiol biosynthesis and metabolism. Phyto-
chemicals isolated from vegetable extracts effectively
suppress the activity of the aromatase enzymes, which are
responsible for conversion of androgens to oestrogens
[32]. Isoflavone concentrations of 1–10 µmol/l similarly
reduced by 50% the activity of the oestradiol biosynthetic
enzymes 3β-hydroxysteroid dehydrogenase and 17β-
hydroxysteroid dehydrogenase [10]. The daily ingestion of
113–202 mg isoflavones by premenopausal women
correlated with a 40% increase in the urinary excretion of
2-hydroxyoestrone, a putative anticancer metabolite of
17β-oestradiol [33]. The above studies thus suggest a
dual chemoprotectant mechanism of soy, in which the
isoflavones suppress steroid hormone biosynthesis while
promoting the metabolism of oestradiol to the protective
2-hydroxylated metabolites.
Despite their apparent effect on endogenous hormone
levels, the role of phyto-oestrogens in breast cancer
initiation and development is unclear. Few studies to date
have addressed the effects of long-term phyto-oestrogen
exposure in humans. Daily dietary supplementation with
45 mg soy isoflavone for 14 days correlated with increased
proliferation of normal breast epithelia in a group of 48
premenopausal women [16]. Expression of the ER target
protein progesterone receptor was upregulated, suggest-
ing an oestrogenic effect. An identical trial using a larger
cohort of 84 premenopausal women conversely found no
significant effect of soy consumption on the proliferation of
normal breast tissue [17]. A number of recent epidemio-
logical studies similarly failed to correlate soyfood
consumption with reduced breast cancer risk. A Japanese
prospective study conducted in a cohort of approximately
35,000 women [34] revealed no significant association
between soy consumption during adulthood and breast
cancer incidence. The retrospective analysis of soy food
intake in a multiethnic cohort of non-Asian breast cancer
patients and control individuals residing in the USA similarly
failed to correlate soy intake with breast cancer risk [35].
Increasing epidemiological evidence suggests that the
chemoprotectant effects of phyto-oestrogens are dependent
on lifelong exposure from childhood. A retrospective study
revealed decreased soyfood intake during adolescence in
a cohort of 1459 Chinese breast cancer patients, as
compared with age-matched control individuals [36]. Daily
soy consumption between the ages of 13 and 15 was
estimated at 6.45 g in the patient group, increasing to
7.23 g in the control cohort. A potential flaw in the study,
however, concerns the ability of women up to the age of
64 years to recall accurately the precise soyfood quantities
consumed many years earlier during adolescence. These
observations may nonetheless explain the apparent lack of
a growth inhibitory effect of soy isoflavones in the adult
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dietary intervention studies discussed above. Isoflavones
are detectable in breast milk following soy consumption
[15], implying that the lower breast cancer incidence in
Asian countries may be attributable to phyto-oestrogen
exposure from birth via breast-feeding. Rodent studies
have accordingly revealed the effective transfer of
genistein from maternal milk to offspring [37].
Rodent breast cancer models
Most available information regarding the effects of phyto-
oestrogens on tumour initiation and the growth of pre-
existing tumours is derived from rodent studies. A number
of similarities do exist between mammary gland develop-
ment in rodents and humans. In both species the
differentiation of breast tissue to form lobules and terminal
end-bud structures occurs prepubertally. Further maturation
does take place throughout adulthood, giving rise to
alveolar buds, which become alveoli during pregnancy and
lactation [38].
Rodent dietary intervention studies using phyto-oestrogens
have reported chemopreventive activities when feeding is
initiated before puberty, at a time when the mammary
gland is undergoing development [3,38–40]. The consump-
tion of a resveratrol-supplemented diet by adolescent rats
served to decrease sensitivity to the chemical carcinogens
7,12-dimethylbenz(a)anthracene (DMBA) and N-methyl-N-
nitrosaurea [39,40]. DMBA treatment induced mammary
tumours in 45% of the resveratrol-treated rodents,
increasing to 75% in the group receiving a control diet. An
extended tumour latency period in excess of 3 weeks was
observed in the resveratrol treatment groups, with the
resultant tumours retaining a more differentiated
morphology as compared with control animals [18,39].
Resveratrol consumption was also associated with the
reduced mammary expression of a number of proteins that
are putatively involved in malignant progression, including
cyclo-oxygenase-2, matrix metalloprotease-9 and nuclear
factor-κB. Similar findings have been noted in prepubertal
rats fed an isoflavone-containing diet before tumour
initiation using DMBA. Despite having no effect on
mammary tumour incidence, soy isoflavone consumption
was associated with an increased tumour latency period.
The resultant tumours excised from the soy-fed animals
were smaller in size and exhibited a more differentiated
phenotype compared with control animals [42].
It has been proposed that phyto-oestrogens protect
against cancer development in adolescent rodents by
promoting maturation of the mammary gland. Analysis of
breast tissue from prepubertal rats injected with genistein
revealed a decrease in the number of immature terminal
end-buds, together with an increase in the more
differentiated lobules type II [38]. Genistein treatment of
human breast cancer cell lines has similarly been found to
induce the expression of a number of maturation markers,
including casein, lipid droplets and intercellular adhesion
molecule-1 [43].
The effect of soy isoflavones on spontaneous tumour
development was recently investigated using neu-ErbB2
over-expressing transgenic mice, which characteristically
develop multiple mammary tumours during adulthood [40].
Tumour initiation was temporarily delayed following the
consumption of an isoflavone mix, but no chemoprotective
effects were observed in mice consuming either genistein or
daidzein in isolation. An equal rate of tumour growth was
noted in the control and treatment groups, although the
isoflavone group exhibited a lower incidence of lung meta-
stases [40]. Antimetastatic activities of the isoflavones
were similarly revealed in a study in which mice were fed
an isoflavone-supplemented diet before injection with the
metastatic 4526 mammary carcinoma cell line [44]. The
isoflavone diet was continued following surgical excision
of the resultant mammary tumour at a size of 1.0 cm
diameter. Both the incidence and size of macroscopically
detectable lung metastases were significantly reduced in
the soy-fed mice, suggesting a potential clinical
application of soy isoflavones in the prevention of
metastasis. Putative anticancer mechanisms of soy and
isolated phyto-oestrogen compounds using in vitro and in
vivo breast cancer models is summarized in Table 1.
Phyto-oestrogens and tamoxifen
The selective ER modulator tamoxifen is used clinically in
the adjuvant treatment of oestrogen-dependent breast
cancer. The drug is also administered as a prophylactic to
individuals who are at high risk for developing the disease
[45,46]. Side effects associated with tamoxifen therapy
include menopause-like symptoms such as hot flushes,
joint pain, sleep disorders and depression, which may be
reduced by the use of hormone replacement therapy
(HRT) [47,48]. Long-term HRT is associated with an
increased risk for mammary carcinogenesis, and its use by
breast cancer patients is therefore discouraged. As a
natural alternative, patients may self-medicate with soy
isoflavone supplements to alleviate the tamoxifen-induced
menopausal symptoms [49]. Published literature regarding
the ingestion of dietary phyto-oestrogens by breast cancer
patients and survivors is, however, controversial [50,51].
The consumption of genistein by athymic mice
antagonized the ability of tamoxifen to inhibit the
proliferation of oestrogen-dependent mammary tumours
[52]. Tumour suppression by tamoxifen correlated with
decreased expression of the ER-inducible genes
presenelin-2 (pS2) and cyclin D1. Tumour growth was
significantly enhanced in mice simultaneously exposed to
tamoxifen and genistein, whereas levels of pS2 and cyclin
D1 expression were increased. Physiological concentrations
of genistein were similarly found to reverse the anta-
gonistic effects of 4-hydroxytamoxifen on ER signalling
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pathways [53], promoting the binding of ER-α to the
positively acting steroid receptor coactivator (SRC)-1. A
recent tissue culture study conversely reported a synergistic
antiproliferative effect of tamoxifen and genistein [54]. The
proliferation of a panel of dysplastic and cancerous breast
cell lines was inhibited by tamoxifen in a dose-dependent
manner, and growth was more potently suppressed by
combined treatment with tamoxifen and genistein.
Hormone-dependent mechanisms of
phyto-oestrogen action
Oestrogen signalling typically involves the diffusion of
ligand through the cell cytoplasm and subsequent binding
to the nuclear receptor subtypes ER-α and ER-β. Ligand-
bound receptors dimerise and associate with oestrogen
response element (ERE) and activator protein-1 element
located in the promoter region of target genes, thereby
activating transcription. The association between receptor
dimers and DNA response elements is enhanced by the
binding of cofactor proteins, such as amplified in breast
cancer-1, thyroid hormone receptor-associated protein,
SRC-1, glutamate receptor interacting protein-1 and
translation initiation factor-2 [55]. Examples of ERE-
induced genes include PR, c-fos, bcl-2 and cathepsin D,
whereas  pS2 and  cyclin D1 are transcribed via the
activator protein-1 response element.
In breast carcinoma cell lines containing functional ER
subtypes the isoflavones exert a biphasic growth effect,
stimulating cellular proliferation at concentrations below
5 µmol/l and inhibiting growth in a dose-dependent manner
at elevated doses [23,43,56,57]. Growth inhibition corre-
lates with decreased DNA synthesis and cell cycle arrest
at the G2/M checkpoint [23,54,56,58–60]. Current
research suggests a principal signalling role of ER-β in
response to isoflavone exposure [61]. Whereas 17β-
oestradiol binds to ER-α and ER-β with equal affinity, the
soy isoflavones selectively associate with ER-β [62].
Receptor binding assays revealed an eightfold to 16-fold
increase in the affinity of genistein, daidzein and biochanin
A for ER-β as compared with ER-α [63]. In ER-negative
breast cancer cells transfected to express ER-α alone,
genistein was only weakly able to stimulate gene
transcription through the ERE. By contrast, genistein
effectively bound to ER-β and promoted the association of
cofactor proteins, thereby regulating downstream ER-β-
mediated gene transcription [62]. The preferential binding
affinity of genistein for ER-β similarly resulted in a
respective 12,000-fold and 33-fold increase in the
recruitment of translation initiation factor-2 and SRC-1a to
ER-β as compared with ER-α [22]. An enhanced
transcriptional activity in response to genistein was,
however, noted in cells transfected to express both
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Table 1
Summary of the putative anticancer mechanisms of soy and isolated phyto-oestrogen compounds in breast cancer cell lines and
rodent models
Phyto-oestrogen Cellular effect Proposed mechanism
Cell culture studies
Genistein Growth inhibition ↓EGF receptor activity [23]
Induction of cell differentiation [43]
↓AP-1 activity, ↓ERK phosphorylation [58]
↑p21WAF1 [59]
↑TGF-β synthesis [75]
Induction of apoptosis ↑Bax, ↑p53 [67]
Biochanin A Growth inhibition ↓ER 
Resveratrol Growth inhibition ↓NF-κB activation [39]
↑p21WAF1 [66,69]
(–)-Epigallocatechin Induction of apoptosis ↓Bcl-2, ↑Bax [70]
Epigallocatechin-3 gallate Growth inhibition ↓Her-2/neu signalling [71]
Rodent models
Genistein Mammary tumour suppression Induction of terminal differentiation [38]
Resveratrol Mammary tumour suppression ↓NF-κB activation [39]
Soy isoflavone extract Mammary tumour suppression ↓ER-α, ↓PR [42]
Isoflavone mix Reduced metastases Not defined [40,44]
↓ and ↑ indicate a respective reduction or increase in protein levels or activity. AP, activator protein; EGF, epidermal growth factor; ER, oestrogen
receptor; ERK, extracellular signal-related kinase; NF-κB, nuclear factor-κB; TGF, transforming growth factor.124
receptor subtypes as compared with cells solely
expressing ER-β [64]. Although ER-α is itself unable to
mediate isoflavone signal transduction, it was postulated
that the presence of the receptor subtype may enhance
ER-β signalling via the formation of ER-α/β heterodimers.
These observations imply that the precise tissue-specific
effects of the soy isoflavones are dependent on the
expression levels and ratios of ER-α and ER-β. The various
cofactors are similarly expressed in a tissue-specific
manner, therefore further influencing the cellular response
to dietary phyto-oestrogens.
The stilbene resveratrol is structurally similar to the
synthetic oestrogen diethylstilbestrol. Treatment of breast
cancer cell lines with resveratrol represses proliferation in
a dose-dependent manner, inducing G2/M phase cell
cycle arrest [39]. Resveratrol exhibits a relatively weak ER-
binding affinity as compared with oestradiol [65];
however, unlike the soy isoflavones, it is able to bind to
both ER-α and ER-β with equal affinity. In cells transfected
to express either ER-α or ER-β resveratrol was found to
act as an agonist for both receptor subtypes, stimulating
ERE transcriptional activity through either ER-α or ER-β
alone [21]. Similar agonist activity was observed in MCF-7
breast cancer cells, which predominantly express the ER-α
isoform. Resveratrol induced the dose-dependent activation
of ERE-mediated transcription, also upregulating the
expression of the ER target genes pS2 and  PR [65].
Recent studies proposed that the cell cycle inhibitor
protein p21WAF1 is a potential downstream target of
resveratrol-induced ER signalling pathways [66]. The
treatment of ER-α-expressing breast cancer cells with
resveratrol resulted in a 23-fold increase in p21WAF1 gene
expression, as determined by cDNA microarray analysis.
The resveratrol-mediated induction of p21WAF1 was
blocked by treatment with the pure anti-oestrogen ICI
182,780, confirming p21WAF1 gene regulation as an ER-
mediated event.
Hormone-independent mechanisms
At concentrations in excess of 25 µmol/l, the soy
isoflavones are capable of inducing apoptosis in human
breast cancer cells [23,67–69]. ER-negative cell lines
retain sensitivity to the apoptotic effects of soy iso-
flavones, thereby confirming that apoptosis occurs in a
hormone-independent manner. Apoptosis was effectively
induced in the ER-α-negative MDA-MB-231 breast cancer
cell line by genistein and daidzein concentrations of
50–100 µmol/l [59,60]. In MCF-7 cell cultures the
induction of cell death by treatment with genistein coincided
with the increased expression of the proapoptotic proteins
Bax and p53 [67]. Breast cancer cell lines expressing
mutant p53 also undergo apoptosis in response to phyto-
oestrogen treatment, thereby implying apoptosis induction
by both p53-dependent and p53-independent mechanisms
[67,70]. The polyphenol epigallocatechin (EGC) is
principally found in green tea and is proposed to have
anticancer properties. Treatment of p53-mutant breast
cancer cells with 100 µmol/l EGC induced a 40%
increase in apoptosis, correlating with increased Bax
expression and reduced levels of the antiapoptotic protein
Bcl-2 [70]. EGC-induced apoptosis was abolished
following treatment with anti-Fas neutralizing antibodies or
caspase inhibitors, suggesting the involvement of Fas
signalling pathways. Although phyto-oestrogen compounds
are effective inducers of apoptosis in cell culture models,
it is unlikely that plasma isoflavone concentrations would
accumulate to the required levels for the activation of
apoptotic pathways in vivo. It is estimated that plasma
phyto-oestrogen concentrations may reach a maximum of
2–4 µmol/l following the moderate consumption of soy
products [15,52], although it is possible that higher levels
may be present in target tissues. In a recently reported
study, equol concentrations within breast tissue were
found to exceed serum levels; however, the reverse was
true for genistein and daidzein [28]. A recent in vitro study
[68] revealed the flavone baicalein to be a more potent
inducer of apoptosis than genistein. Baicalein is isolated
from the plant Scutellariae radix and is a common
ingredient in herbal tea preparations. A concentration of
10 µmol/l baicalein induced significant cell death in
MCF-7 cell cultures, suggesting baicalein as a potentially
useful pharmacological agent in breast cancer therapy.
Dietary phyto-oestrogens are capable of inhibiting the
proliferation of hormone-independent breast cell lines
[43,54,58,69]. It has been proposed that growth inhibition
in the absence of functional ER occurs via the inhibition of
tyrosine kinase activity. The protein tyrosine kinases are
involved in a number of growth factor signalling pathways,
including transforming growth factor (TGF)-α, insulin-like
growth factor (IGF)-I, IGF-II and epidermal growth factor
(EGF). In ER-negative breast cancer cultures 5 µmol/l
genistein negated the stimulatory effects of TGF-α, IGF-I
and IGF-II, implying the inhibition of tyrosine kinase activity
[23]. The human EGF receptor-2 oncogene (Her-2) is
constitutively overexpressed in approximately 30% of
breast cancers and is associated with a poor patient
prognosis [71]. Research using breast cancer cell lines
suggests that dietary phyto-oestrogens are capable of
repressing EGF receptor activity. The inhibition of tyrosine
kinase activity by 5 µmol/l genistein in MCF-7 cells corre-
lated with the repression of EGF receptor tyrosine phos-
phorylation in response to EGF stimulation [23]. Similar
findings were reported in a recent study investigating the
chemoprotective effects of the green tea polyphenol
epigallocatechin-3 gallate (EGCG). The treatment of Her-2/
neu over-expressing mouse mammary cells with 20–80 µg/ml
EGCG inhibited proliferation in a dose-dependent manner,
correlating with a reduction in Her-2/neu signalling activity
[72]. The basal tyrosine phosphorylation of Her-2/neu was
decreased by approximately 96% following treatment with
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80 µg/ml EGCG. Downstream activities of the signalling
proteins phosphoinositide 3-kinase, Akt and nuclear factor-
κB were similarly repressed, suggesting a potential clinical
application of EGCG in breast cancer therapy.
The soy isoflavones have additionally been proposed to
regulate the proliferation of breast epithelia via an
alternative mechanism involving the modulation of TGF-β
synthesis [73]. In normal mammary tissue TGF-β maintains
proliferative homeostasis by inhibiting the growth of
epithelial cells [74,75]. The incubation of human mammary
epithelial cells with 5 µmol/l genistein induced a fivefold
increase in the level of TGF-β secretion [76]. The further
analysis of media conditioned with human mammary
epithelial cells revealed the presence of the active as
opposed to latent form of TGF-β, thus implying a direct
link between soy isoflavones and the TGF-β signalling
pathway.
Conclusion
This review highlights current ambiguities regarding the
precise role of phyto-oestrogens in breast cancer chemo-
prevention. Phyto-oestrogens were originally proposed as
cancer protective agents following epidemiological
observations revealing a low breast cancer incidence in
soy-consuming populations. However, later research failed
to ascertain a preventive role of phyto-oestrogens in
breast cancer, possibly because of lack of long-term
human dietary intervention trials. Although existing short-
term studies do suggest an association between phyto-
oestrogen consumption and a favourable steroid hormone
profile, the precise effects on mammary cell proliferation
remain unclear. The apparent lack of proliferative effects in
adult dietary trials may be explained by both rodent
studies and retrospective dietary recall studies, which
suggest that breast cancer chemoprevention during
adulthood is critically dependent on the prior consumption
of phyto-oestrogens during adolescence. The physiological
effects of phyto-oestrogens may be further influenced by
additional factors such as ER expression status within the
mammary tissue, precise quantities of phyto-oestrogens
ingested and the ability to produce active metabolites.
Although the role of dietary phyto-oestrogens in breast
cancer chemoprevention remains inconclusive, rodent
studies encouragingly suggest that soy products may
possess antitumour activities. Mammary tumours in phyto-
oestrogen-fed rodents typically develop with an increased
latency period, are smaller in size, are better differentiated
and have a reduced capacity for metastasis. Perhaps the
most clinically promising data concern the ability of phyto-
oestrogen compounds to inhibit the proliferation of ER-
negative breast cancer cultures and tumour xenografts in
rodents. Although ER-positive cells are often growth stimu-
lated by low phyto-oestrogen concentrations, stimulatory
effects have not been reported in cells devoid of functional
ER. Phyto-oestrogen compounds may thus potentially
prove to be clinically useful for the treatment of ER-
negative breast tumours that are typically unresponsive to
traditional tamoxifen hormonal therapy. Although current
data regarding self-medication with phyto-oestrogens by
breast cancer patients remain controversial, the published
literature does imply that these compounds may prove to
be promising agents for future use in cancer therapy.
Clinical trials are warranted to compare the efficacy of
phyto-oestrogens with that of conventional endocrine
therapies, and to assess their efficacy as alternatives to
HRT to alleviate menopausal symptoms. The latter is
especially pertinent given that the premature termination
of the HABITS (Hormonal Replacement Therapy After
Breast Cancer – Is It Safe?) trial [77] may lead to
increased phyto-oestrogen use.
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